NCT05519111View on ClinicalTrials.gov

Cannabinoids for the Reduction of Inflammation and Sickle Cell Related Pain

PHASE2RecruitingINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

April 3, 2025

Primary Completion Date

April 1, 2027

Study Completion Date

May 1, 2027

Conditions
Sickle Cell Disease
Interventions
DRUG

Dronabinol

Dronabinol, an FDA approval oral agent containing synthetic tetrahydrocannabinol (THC)

DRUG

Placebo

placebo equivalent

Trial Locations (1)

10029

RECRUITING

Mount Sinai Hospital, New York

All Listed Sponsors
collaborator

National Heart, Lung, and Blood Institute (NHLBI)

NIH

lead

Icahn School of Medicine at Mount Sinai

OTHER